Other languages Immutep ADR Deutsche Boerse AG

Equities

YP1A

US45257L1089

Market Closed - Deutsche Boerse AG Other stock markets 07:09:28 2024-07-11 am EDT			5-day change	1st Jan Change
1.76 ^EUR	-1.68%		-2.22%	-16.98%

06:53am	Immutep Surges 19% Following Positive Results in Head, Neck Cancer Trial	MT
Jun. 28	Immutep Reports Positive Topline Results from TACTI-003 Phase IIb Trial in First Line Head and Neck Cancer	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Immutep Surges 19% Following Positive Results in Head, Neck Cancer Trial	12:53am
Immutep Reports Positive Topline Results from TACTI-003 Phase IIb Trial in First Line Head and Neck Cancer	Jun. 28
Wall Street Set to Open Marginally Lower Thursday as Investors Parse Bullish Economic Data	Jun. 27
Immutep Reports Positive Results in Drug Combination Trial for Head, Neck Cancer	Jun. 27
Immutep Gets Exclusive Rights to Develop, Commercialize New Anti-LAG-3 Small Molecules	Jun. 25
Immutep Completes Stock Offering	Jun. 05
Immutep Limited Announces Clinical Collaboration with Msd to Evaluate Efti in Combination with Keytruda®? (Pembrolizumab) in Pivotal Phase Iii Trial	Jun. 02
Immutep Says Safety Lead-in Phase of Breast Cancer Study Yields 'Encouraging' Data	May. 15
Immutep Limited Presents Data from Safety Lead-In Phase of AIPAC-003 at ESMO Breast 2024	May. 15
Immutep Limited Announces Initial Clinical Data from EFTISARC-NEO	May. 03
Immutep Limited Reports Positive Initial Clinical Data Reported from Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma	May. 02
Immutep Validates Initial Efficacy of Immunotherapy Medication in Phase Two Cancer Trial	May. 01
Immutep Limited Provides an Update on the Ongoing Development of its Product Candidates, eftilagimod Alpha and IMP761 for the Quarter Ended 31 March 2024	Apr. 30
Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Phase IIb Trial Evaluating Efti in Combination With KEYTRUDA in First Line Metastatic Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression	Apr. 25
Immutep Shows Positive Data in Trial to Treat Squamous Cell Cancers in Head, Neck	Apr. 24
Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Cohort B	Apr. 24
Immutep Limited Appoints Leading Research Institute to Conduct First-In-Human Phase I Study of IMP761	Apr. 18
Immutep Limited Receives Positive Feedback from the Spanish Medicines Agency for Upcoming Tacti-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer	Apr. 17
Australian Shares Tick Down as US Fed Chair Flags Likely Rate Cut Delay	Apr. 17
Immutep Limited Announces First Clinical Data from 90Mg Dosing of Efti	Mar. 05

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Immutep ADR Deutsche Boerse AG

Equities

YP1A

US45257L1089

Other languages

Filters